Genitourinary Drugs Market 2025–2034: In-Depth Forecast on Size, Growth Drivers, Trends & Competitive Outlook

The Business Research Company's Genitourinary Drugs Market 2025–2034: In-Depth Forecast on Size, Growth Drivers, Trends & Competitive Outlook

LONDON, GREATER LONDON, UNITED KINGDOM, July 2, 2025 /EINPresswire.com/ -- Save 30% on all global market reports with code ONLINE30 - stay informed on tariff changes, macroeconomic trends, and more.

The genitourinary drugs market size is projected for significant gains in the years to come. From a value of $30.07 billion in 2024, predictions assert a rise to $31.02 billion by 2025, reporting a compound annual growth rate CAGR of 3.2%. This steady growth can be tied back to rising incidences of urinary tract infections, a spurt in cases of benign prostatic hyperplasia, a growing awareness of sexual health, an aging population, and increased reports of chronic kidney diseases.

What Is The Anticipated Growth Rate And Market Size Of The Genitourinary Drugs Market?

A further climb is expected in the genitourinary drugs market size within the next decade. Projections show a rise to $34.76 billion by 2029, indicating a CAGR of 2.9%. This future trajectory can largely be attributed to an ongoing prevalence of urinary tract infections and heightened consciousness about sexual health, complemented by an enlarging healthcare infrastructure. A greater demand for hormone replacement therapies and an increasing use of oral contraceptives also contribute. Critical trends in the coming period include advancements in drug formulations and delivery systems, integration of digital health solutions, personalized medicine approaches driven by technology, developments in biologic therapies, and advancements in precision medicine.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24548&type=smp

Why Is The Genitourinary Drugs Market Expected To Grow?

A rising prevalence of genitourinary disorders worldwide is anticipated to pump the growth of the genitourinary drugs market in the foreseeable future. These disorders—the afflictions of the genitourinary system encompassing both the urinary and the reproductive organs—include infections, cancers, and functional or structural issues. Owing to age-related changes and an aging population, the prevalence of such disorders, and thus their associated risk, are amplifying. Genitourinary drugs have been instrumental in managing these disorders, targeting conditions of both the urinary and reproductive systems specifically. They offer respite from infections, inflammation, and dysfunction, and in doing so, have improved patient outcomes by implementing effective, convenient, and condition-specific treatment, thus enhancing overall quality of life.

Who Are The Major Players In The Genitourinary Drugs Market?

Major companies participating in the genitourinary drugs market encompass a wide range, namely Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Ipsen Société Anonyme, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals Public Limited Company, Zydus Lifesciences Limited, Endo International Public Limited Company, Takeda Pharmaceutical Company Limited, Melinta Therapeutics Inc., Asieris Pharmaceuticals, Sun Pharmaceutical Industries Ltd.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/genitourinary-drugs-global-market-report

What Are The Market Trends In The Genitourinary Drugs Industry?

The leading companies in the genitourinary drugs market are focusing on the development of innovative products—such as oral antibiotics—to enhance treatment convenience, improve patient adherence, and fight infections effectively. For instance, in March 2025, GSK plc, a UK-based pharmaceutical company, received approval from the US Food and Drug Administration FDA for Blujepa gepotidacin for treating uncomplicated urinary tract infections caused by susceptible bacteria in women and girls aged 12 and older. As a first-in-class oral antibiotic, it works by inhibiting bacterial DNA replication, targeting two critical enzymes—DNA gyrase and topoisomerase IV. Blujepa offers a unique mechanism compared to traditional antibiotics, binding to unique sites to overcome resistance, thereby promising improved safety and efficacy.

What Does The Genitourinary Drugs Market Segmentation Look Like?

The genitourinary drugs market is segmented as follows:

1 By Product: Urologicals, Hormonal Therapy, Gynecological, Anti-Infectives, Other Products
2 By Route Of Administration: Oral, Parenteral, Topical
3 By Application: Urinary Tract Infections UTIs, Benign Prostatic Hyperplasia BPH, Prostate Cancer, Overactive Bladder, Bladder Cancer, Other Applications
4 By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

Where additions to segments are included:

1 By Urologicals: Benign Prostatic Hyperplasia BPH Drugs, Urinary Incontinence Drugs, Overactive Bladder OAB Drugs, Urolithiasis Kidney Stone Drugs, Erectile Dysfunction Drugs
2 By Hormonal Therapy: Estrogen Therapy, Progestin Therapy, Gonadotropin-Releasing Hormone GnRH Agonists/Antagonists, Androgen Replacement Therapy, Selective Estrogen Receptor Modulators SERMs
3 By Gynecological: Contraceptives, Menopausal Hormone Therapy, Fertility Drugs, Drugs for Endometriosis, Drugs for Polycystic Ovary Syndrome PCOS
4 By Anti-Infectives: Urinary Tract Infection UTI Drugs, Sexually Transmitted Infection STI Drugs, Vaginal Antifungals, Antivirals
5 By Other Products: Drugs for Chronic Pelvic Pain, Bladder Cancer Therapies, Interstitial Cystitis Drugs, Pelvic Organ Prolapse Treatment Drugs, Adjunctive Therapies

What Does The Regional Breakdown Of The Genitourinary Drugs Market Look Like?

North America led the largest portion of the genitourinary drugs market in 2024. However, Asia-Pacific is anticipated to be the fastest-growing region in the forecast period. The regions covered in the genitourinary drugs market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
https://www.thebusinessresearchcompany.com/report/genitourinary-drugs-global-market-report
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report
Oral Transmucosal Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report
Antiparasitic Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries sheltering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. With access to 1,500,000 datasets, the advantage of in-depth secondary research, and exclusive insights from industry leaders, navigate the business sphere with the information needed to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+ +44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X